ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

atebimetinib

Also written as “Atebimetinib”, “IMM-1-104 Monotherapy (Treatment Group A)” and “IMM-1-104 + modified FOLFIRINOX (Treatment Group C)”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Pancreatic Neoplasms · Melanoma, Cutaneous Malignant, led by Immuneering.

Drug pageAtebimetinib: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Apr 20, 20263 company-led studies, 3 open or runningNext primary completion: Jun 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Immuneering33 open or runningphase 3since Apr 20, 2026Oct 14, 2022Jun 2027phase 2 · NCT05585320

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Oct 14, 2022First study: phase 2 study in Melanoma, Cutaneous MalignantFirst studyNCT05585320 · 209 enrolled · United States
  2. Feb 13, 2025Named atebimetinibINNProposed as its International Nonproprietary Name in WHO's List 132
  3. Apr 20, 2026Phase 3 study in Pancreatic NeoplasmsPhase 3 reachedNCT07562152 · 570 planned · United States, Australia, Georgia and more
  4. Nov 6, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07946848 · 100 planned

Ahead

  1. Jun 2027Primary completion: phase 2 study in Melanoma, Cutaneous MalignantNCT05585320
  2. Jun 2028Primary completion: phase 3 study in Pancreatic NeoplasmsNCT07562152
  3. May 2029Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07946848

TargetBeta

MAP2K2 →read by rule
“An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK/ERK kinase; MEK) 1 and MEK2, ”NCIt, by rule

Other programs on MAP2K2

ProgramCompanyFurthest phaseStudies
cobimetinibruleHoffmann-La Rochephase 338
pimasertibruleMerck KGaA, Darmstadt, Germanyphase 213
mirdametinibruleMerck KGaA, Darmstadt, Germanyphase 29
polfurmetinibPfizerphase 13

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07946848Carcinoma, Non-Small-Cell Lung2Not yet recruitingMay 2029100
NCT07562152Pancreatic Neoplasms · United States, Australia, Georgia and more3RecruitingJun 2028570
NCT05585320Melanoma, Cutaneous Malignant · United States2Active, not recruitingJun 2027209

How it is read

Names in the registry

  • “Atebimetinib”, 2 entries
  • “IMM-1-104 Monotherapy (Treatment Group A)”, 1 entry
  • “IMM-1-104 + modified FOLFIRINOX (Treatment Group C)”, 1 entry
  • “IMM-1-104 + dabrafenib (Treatment Group D)”, 1 entry
  • “IMM-1-104 + pembrolizumab (Treatment Group E)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.